

# Junnian Zheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4212664/publications.pdf>

Version: 2024-02-01

135  
papers

4,592  
citations

172386

29  
h-index

138417

58  
g-index

142  
all docs

142  
docs citations

142  
times ranked

6377  
citing authors

#	ARTICLE	IF	CITATIONS
1	Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 118.e1-118.e5.	0.6	4
2	Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 14-25.	2.0	14
3	Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 1-13.	2.0	6
4	CD36 regulates LPS-induced acute lung injury by promoting macrophages M1 polarization. <i>Cellular Immunology</i> , 2022, 372, 104475.	1.4	16
5	Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas. <i>Molecular Cancer</i> , 2022, 21, 13.	7.9	43
6	C1QBP regulates T cells mitochondrial fitness to affect their survival, proliferation and anti-tumor immune function. <i>Cancer Science</i> , 2022, , .	1.7	9
7	Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity. <i>Pharmacological Research</i> , 2022, 175, 106034.	3.1	6
8	Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation. <i>Cell Death and Disease</i> , 2022, 13, 99.	2.7	21
9	iNKT: A new avenue for CAR-based cancer immunotherapy. <i>Translational Oncology</i> , 2022, 17, 101342.	1.7	14
10	Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, 711-718.	2.0	3
11	Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2246-2256.	0.8	43
12	Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma. <i>Frontiers in Immunology</i> , 2022, 13, 814548.	2.2	7
13	MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation <i>In Vivo</i> . <i>Cancer Research</i> , 2021, 81, 898-909.	0.4	22
14	Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 250-258.	0.7	14
15	Simultaneous silencing Aurora-A and UHRF1 inhibits colorectal cancer cell growth through regulating expression of DNMT1 and STAT1. <i>International Journal of Medical Sciences</i> , 2021, 18, 3437-3451.	1.1	3
16	Blockade of AIM2 inflammasome or Î±1-AR ameliorates IL-1Î² release and macrophage-mediated immunosuppression induced by CAR-T treatment. , 2021, 9, e001466.		31
17	A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
18	Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer. <i>Journal of Cancer</i> , 2021, 12, 1846-1852.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Humanized CD19-targeted chimeric antigen receptor (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E162-E165.	2.0	12
20	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 611366.	2.2	41
21	DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution. <i>Oncogene</i> , 2021, 40, 1884-1895.	2.6	27
22	LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 52.	3.5	112
23	Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 273.e1-273.e5.	0.6	4
24	Absent in melanoma 2-mediating M1 macrophages facilitate tumor rejection in renal carcinoma. <i>Translational Oncology</i> , 2021, 14, 101018.	1.7	9
25	Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 663517.	1.3	8
26	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. <i>Journal of Affective Disorders</i> , 2021, 286, 33-39.	2.0	6
27	An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 691064.	1.3	15
28	Trim21-mediated HIF-1 $\alpha$ degradation attenuates aerobic glycolysis to inhibit renal cancer tumorigenesis and metastasis. <i>Cancer Letters</i> , 2021, 508, 115-126.	3.2	37
29	Co-immunization with Myc enhances CD8 <sup>+</sup> or CD103 <sup>+</sup> DCs mediated tumor-specific multi-functional CD8 <sup>+</sup> T cell responses. <i>Cancer Science</i> , 2021, 112, 3469-3483.	1.7	8
30	A p53/CPEB2 negative feedback loop regulates renal cancer cell proliferation and migration. <i>Journal of Genetics and Genomics</i> , 2021, 48, 606-617.	1.7	7
31	The molecular mechanism of acute liver injury and inflammatory response induced by Concanavalin A. <i>Molecular Biomedicine</i> , 2021, 2, 24.	1.7	11
32	Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. <i>Pharmacological Research</i> , 2021, 174, 105829.	3.1	15
33	Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinoma. <i>Molecular Immunology</i> , 2021, 139, 184-192.	1.0	2
34	Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 755549.	2.2	12
35	Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 11063-11074.	1.6	12
36	PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 1080.	2.7	31

#	ARTICLE	IF	CITATIONS
37	Neutrophil Extracellular Traps in Digestive Cancers: Warrior or Accomplice. <i>Frontiers in Oncology</i> , 2021, 11, 766636.	1.3	7
38	Vitamin C through upregulating SYNPO2 level suppresses the proliferation and migration of glioma cells. <i>Jbuon</i> , 2021, 26, .	0.3	0
39	CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. <i>Journal of Immunotherapy</i> , 2020, 43, 16-28.	1.2	53
40	Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 865-875.	2.0	51
41	Manipulation of Mitochondrial Plasticity Changes the Metabolic Competition Between "Foe" and "Friend" During Tumor Malignant Transformation. <i>Frontiers in Oncology</i> , 2020, 10, 1692.	1.3	6
42	Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10744-10755.	1.6	4
43	&lt;p&gt;MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10001-10012.	1.0	7
44	Macrophages-stimulated PRMT1-mediated EZH2 methylation promotes breast cancer metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 679-684.	1.0	19
45	Î2â€AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells. <i>Cancer Science</i> , 2020, 111, 4417-4428.	1.7	11
46	Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. <i>Cell Death and Differentiation</i> , 2020, 27, 3226-3242.	5.0	87
47	Post-translational modifications of EZH2 in cancer. <i>Cell and Bioscience</i> , 2020, 10, 143.	2.1	47
48	The optimization system for preparation of TG1 competent cells and electrotransformation. <i>MicrobiologyOpen</i> , 2020, 9, e1043.	1.2	6
49	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
50	Turning Cold into Hot: Firing up the Tumor Microenvironment. <i>Trends in Cancer</i> , 2020, 6, 605-618.	3.8	562
51	Birth Weight and Stroke in Adult Life: Genetic Correlation and Causal Inference With Genome-Wide Association Data Sets. <i>Frontiers in Neuroscience</i> , 2020, 14, 479.	1.4	15
52	Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. <i>Leukemia</i> , 2020, 34, 2704-2707.	3.3	21
53	Phase II trial of co-administration of CD19â€and CD20â€targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 5827-5838.	1.3	36
54	The SKI proto-oncogene restrains the resident CD103+CD8+ T cell response in viral clearance. <i>Cellular and Molecular Immunology</i> , 2020, 18, 2410-2421.	4.8	11

#	ARTICLE	IF	CITATIONS
55	Translation and functional roles of circular RNAs in human cancer. <i>Molecular Cancer</i> , 2020, 19, 30.	7.9	422
56	The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines. <i>Cell Death and Disease</i> , 2020, 11, 31.	2.7	24
57	HCRP-1 regulates cell migration, invasion and angiogenesis via Src/ FAK signaling in human prostate cancer. <i>International Journal of Biological Sciences</i> , 2020, 16, 342-352.	2.6	8
58	Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin Against Renal Cell Carcinoma. <i>Human Gene Therapy</i> , 2020, 31, 651-663.	1.4	19
59	DCAF1 regulates Treg senescence via the ROS axis during immunological aging. <i>Journal of Clinical Investigation</i> , 2020, 130, 5893-5908.	3.9	71
60	A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e521-e529.	2.2	211
61	Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 2751-2753.	3.3	12
62	Selective pericellular hydrogelation by the overexpression of an enzyme and a membrane receptor. <i>Nanoscale</i> , 2019, 11, 13714-13719.	2.8	30
63	PTBP3 contributes to colorectal cancer growth and metastasis via translational activation of HIF-1 $\alpha$ . <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 301.	3.5	30
64	PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway. <i>Angiogenesis</i> , 2019, 22, 507-519.	3.7	30
65	Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 362.	3.5	20
66	A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin. <i>Medical Oncology</i> , 2019, 36, 96.	1.2	2
67	Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1988.	2.2	25
68	High FOXK1 expression correlates with poor outcomes in hepatocellular carcinoma and regulates stemness of hepatocellular carcinoma cells. <i>Life Sciences</i> , 2019, 228, 128-134.	2.0	15
69	Rap2B promotes cell adhesion, proliferation, migration and invasion of human glioma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 221-229.	1.4	8
70	ISG12a and its interaction partner NR4A1 are involved in TRAIL $\alpha$ -induced apoptosis in hepatoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3520-3529.	1.6	11
71	Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer. <i>International Immunopharmacology</i> , 2019, 70, 125-134.	1.7	16
72	Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. <i>BMC Medicine</i> , 2019, 17, 225.	2.3	63

#	ARTICLE	IF	CITATIONS
73	Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer. <i>Translational Oncology</i> , 2019, 12, 453-461.	1.7	10
74	Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 323-334.	1.9	24
75	Neural regulation of drug resistance in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 20-28.	3.3	8
76	Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Phase II Trial. <i>Blood</i> , 2019, 134, 1590-1590.	0.6	7
77	Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3872-3872.	0.6	4
78	Discoïdin domain receptor 1: New star in cancer-targeted therapy and its complex role in breast carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 3403-3408.	0.8	23
79	Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, 851-858.	2.0	138
80	A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. <i>Cancer Biology and Therapy</i> , 2018, 19, 475-483.	1.5	25
81	H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma. <i>British Journal of Cancer</i> , 2018, 118, 522-533.	2.9	17
82	JNK1/2 and ERK1/2 provides vital clues about tumor recurrence and survival in hepatocellular carcinoma patients. <i>Future Oncology</i> , 2018, 14, 2471-2481.	1.1	8
83	The role of Aurora-A in cancer stem cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 98, 89-92.	1.2	23
84	PTBP3-Mediated Regulation of ZEB1 mRNA Stability Promotes Epithelial-Mesenchymal Transition in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 387-398.	0.4	75
85	Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment. <i>Oncotarget</i> , 2018, 9, 5480-5491.	0.8	118
86	RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. <i>Immunity</i> , 2018, 49, 886-898.e5.	6.6	15
87	DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF- $\kappa$ B pathway. <i>Oncology Reports</i> , 2018, 40, 968-978.	1.2	17
88	HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer. <i>Cell Death and Disease</i> , 2018, 9, 1176.	2.7	24
89	Bortezomib improves adoptive carbonic anhydrase IX-specific chimeric antigen receptor-modified NK92 cell therapy in mouse models of human renal cell carcinoma. <i>Oncology Reports</i> , 2018, 40, 3714-3724.	1.2	11
90	Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/ $\beta$ -catenin signaling pathway in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 7082-7090.	0.8	21

#	ARTICLE	IF	CITATIONS
91	Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	0.9	92
92	The development of CAR design for tumor CAR-T cell therapy. <i>Oncotarget</i> , 2018, 9, 13991-14004.	0.8	31
93	Downregulation of Frizzled-7 induces the apoptosis of hepatocellular carcinoma cells through inhibition of NF- $\kappa$ B. <i>Oncology Letters</i> , 2018, 15, 7693-7701.	0.8	6
94	H1<sup>p</sup>AIM<sup>2</sup> nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5670-5681.	1.6	17
95	AIM2 is a potential therapeutic target in human renal carcinoma and suppresses its invasion and metastasis via enhancing autophagy induction. <i>Experimental Cell Research</i> , 2018, 370, 561-570.	1.2	38
96	The Emerging Roles of RASSF5 in Human Malignancy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 314-322.	0.9	15
97	Disturbance of Mammary UDP-Glucuronosyltransferase Represses Estrogen Metabolism and Exacerbates Experimental Breast Cancer. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2152-2162.	1.6	11
98	Cleavage and phosphorylation: important post-translational modifications of galectin-3. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 367-374.	2.7	17
99	Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1099-1106.	1.1	21
100	Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770165.	0.8	25
101	Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17013.	7.1	14
102	Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 21614-21622.	1.6	11
103	Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	62
104	Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma. <i>Oncology Reports</i> , 2017, 37, 3405-3414.	1.2	21
105	iRGD as a tumor-penetrating peptide for cancer therapy. <i>Molecular Medicine Reports</i> , 2017, 15, 2925-2930.	1.1	49
106	RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis. <i>Oncotarget</i> , 2017, 8, 101042-101056.	0.8	24
107	Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. <i>Oncotarget</i> , 2017, 8, 9488-9499.	0.8	18
108	p53 upregulates PLC $\beta$ -IP3-Ca <sup>2+</sup> pathway and inhibits autophagy through its target gene Rap2B. <i>Oncotarget</i> , 2017, 8, 64657-64669.	0.8	8

#	ARTICLE	IF	CITATIONS
109	ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer. <i>Oncotarget</i> , 2016, 7, 79017-79031.	0.8	21
110	Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC. <i>Oncology Letters</i> , 2016, 12, 3241-3249.	0.8	18
111	Discoidin domain receptor 1 (DDR1), a promising biomarker, induces epithelial to mesenchymal transition in renal cancer cells. <i>Tumor Biology</i> , 2016, 37, 11509-11521.	0.8	30
112	Estrogen potentiates reactive oxygen species (ROS) tolerance to initiate carcinogenesis and promote cancer malignant transformation. <i>Tumor Biology</i> , 2016, 37, 141-150.	0.8	21
113	Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. <i>Cancer Biology and Therapy</i> , 2016, 17, 664-673.	1.5	7
114	The emerging role of RUNX3 in cancer metastasis (Review). <i>Oncology Reports</i> , 2016, 35, 1227-1236.	1.2	91
115	Rap2B GTPase: structure, functions, and regulation. <i>Tumor Biology</i> , 2016, 37, 7085-7093.	0.8	8
116	Structure, functional regulation and signaling properties of Rap2B. <i>Oncology Letters</i> , 2016, 11, 2339-2346.	0.8	14
117	Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 379, 213-219.	3.2	52
118	Rap2B promotes cell proliferation, migration and invasion in prostate cancer. <i>Medical Oncology</i> , 2016, 33, 58.	1.2	26
119	Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer. <i>International Immunopharmacology</i> , 2016, 40, 327-331.	1.7	24
120	A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer. <i>Oncotarget</i> , 2016, 7, 48309-48320.	0.8	5
121	HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 13470.	1.6	23
122	Rap2B promotes proliferation, migration and invasion of human breast cancer through calcium-related ERK1/2 signaling pathway. <i>Scientific Reports</i> , 2015, 5, 12363.	1.6	70
123	The Pleiotropic Effects of miRNAs on Tumor Angiogenesis. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1807-1815.	1.2	7
124	DNA damage response – A double-edged sword in cancer prevention and cancer therapy. <i>Cancer Letters</i> , 2015, 358, 8-16.	3.2	155
125	p53-mediated autophagic regulation: A prospective strategy for cancer therapy. <i>Cancer Letters</i> , 2015, 363, 101-107.	3.2	83
126	PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF- $\kappa$ B/MMP-9 signaling pathway. <i>Molecular Cancer</i> , 2015, 14, 66.	7.9	53



#	ARTICLE	IF	CITATIONS
127	A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. PLoS ONE, 2015, 10, e0129865.	1.1	26
128	Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models. Oncotarget, 2015, 6, 1079-1089.	0.8	17
129	Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer. Oncotarget, 2015, 6, 19148-19162.	0.8	14
130	Role of Rap2 and its Downstream Effectors in Tumorigenesis. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 1269-1276.	0.9	5
131	Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells. Oncology Letters, 2014, 8, 575-581.	0.8	8
132	Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells. Virus Research, 2014, 181, 61-71.	1.1	14
133	SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. Oncology Reports, 2014, 32, 2533-2540.	1.2	14
134	Role of RUNX3 in Suppressing Metastasis and Angiogenesis of Human Prostate Cancer. PLoS ONE, 2014, 9, e86917.	1.1	35
135	BRMS1 Suppresses Glioma Progression by Regulating Invasion, Migration and Adhesion of Glioma Cells. PLoS ONE, 2014, 9, e98544.	1.1	24